Skip to main content
ARS Home » Southeast Area » Oxford, Mississippi » Natural Products Utilization Research » Research » Publications at this Location » Publication #315057
Title: Epigenetic potential of resveratrol and analogs in preclinical models of prostate cancer

Author
item KUMAR, AVINASH - University Of Mississippi Medical Center
item DHAR, SWATI - University Of Mississippi Medical Center
item Rimando, Agnes
item LAGE, JANICE - University Of Mississippi Medical Center
item LEWIN, JACK - University Of Mississippi Medical Center
item ZHANG, XU - University Of Mississippi Medical Center
item LEVENSON, ANA - University Of Mississippi Medical Center

Submitted to: Annals of the New York Academy of Sciences
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 5/20/2015
Publication Date: 7/27/2015
Publication URL: http://handle.nal.usda.gov/10113/62242
Citation: Kumar, A., Dhar, S., Rimando, A.M., Lage, J.M., Lewin, J.R., Zhang, X., Levenson, A.S. 2015. Epigenetic potential of resveratrol and analogs in preclinical models of prostate cancer. Annals of the New York Academy of Sciences. 1348:1-9.

Interpretive Summary: Dietary polyphenols such as resveratrol possess anticancer properties and, therefore, chemopreventive and therapeutic potentials. Resveratrol has pleiotropic effect exerting its biological activity through multiple pathways and targets associated with cancer. Numerous studies have demonstrated the anticancer effects of resveratrol and to a less extent its analogs, commonly in tissue cultures while in vivo observations are limited. In this review, we provide a concise summary of our results on epigenetic mechanisms of resveratrol and analogs mediated through regulation of metastasis-associated protein and microRNAs, and highlight the anticancer effects of these compounds in animal models of prostate cancer. We also provide summary of data from our studies that show resveratrol analogs with better bioavailability have superior potency and greater anticancer effects.

Technical Abstract: Prostate cancer is affected by lifestyle, particularly diet. Dietary polyphenols such as resveratrol possess anticancer properties and, therefore, chemopreventive and therapeutic potentials. Resveratrol has pleiotropic effect exerting its biological activity through multiple pathways and targets associated with cancer. Numerous studies have demonstrated the anticancer effects of resveratrol and to a less extent its analogs, commonly in tissue cultures while in vivo observations are limited. In this review, we provide a concise summary of our results on epigenetic mechanisms of resveratrol and analogs mediated through regulation of chromatin modifier metastasis-associated protein (MTA1) and microRNAs, and highlight the anticancer effects of these compounds in preclinical models of prostate cancer. It is our hope that identified stilbene responsive mechanism-based biomarkers such as MTA1 and oncomiRs may become indicative of treatment efficacy in prostate cancer. Resveratrol analogs with better bioavailability, therefore conferring superior pharmacological potencies and greater anticancer effects, may be stronger candidates for clinical development.